



NEWS RELEASE

# CRINETICS PHARMACEUTICALS TO PARTICIPATE IN THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

2024-01-03

SAN DIEGO, CA – January 3, 2024 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that **Scott Struthers, Ph.D.**, founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.

Details of the corporate presentation are as follows:

Date: Tuesday, January 9, 2024

Time: 3:45 p.m. Pacific Time

Room: Borgia Room

The live and archived webcast will be accessible on the **Events & Presentations** page in the Investors section on the Crinetics' website at [www.crinetics.com/events](http://www.crinetics.com/events).

If you are interested in arranging a 1×1 meeting with management, please contact your J.P. Morgan representative.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and

commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. **Paltusotine**, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for **CRN04894** a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing's disease and congenital adrenal hyperplasia. All of the Company's **drug candidates** are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

---

Contact:

Chas Schultz

VP, IR & Corporate Communications

**cschultz@crinetics.com**

**(858) 450-6464**

Investors / Media:

Corey Davis

LifeSci Advisors

**cdavis@lifesciadvisors.com**

**(212) 915-2577**

Jenn Gordon

Spectrum Science

**jgordon@spectrumscience.com**

**(202) 957-7795**

Source: Crinetics Pharmaceuticals, Inc.